期刊文献+

局部晚期鼻咽癌放疗同步PF方案或顺铂单药的临床对照研究 被引量:8

Clinical controlled study of PF regimen or cisplatin plus concurrent radiotherapy in locally advanced nasopharyngeal carcinoma
在线阅读 下载PDF
导出
摘要 目的对比观察顺铂(DDP)单药用于局部晚期鼻咽癌同步放化疗与DDP联合氟尿嘧啶(5-FU)方案(PF方案)同步放化疗的有效性和安全性。方法 76例局部晚期鼻咽癌分为两组,40例接受PF方案同步放化疗(5-FU 500mg/m2静滴,d1~d5;DDP 80mg/m2静滴,d1,21天为1周期),36例接受DDP单药同步放化疗(DDP 40mg/m2静滴,每周1次,共7次)。鼻咽部病灶及颈部阳性淋巴结给予放疗总量为70Gy,颈部预防性照射给予放疗量50Gy。结果全部患者均可评价疗效和毒副反应,PF方案组及DDP单药组有效率均为100%。PF方案组的1、3年生存率分别为100%、85%,DDP单药组分别为100%、89%(P>0.05);PF方案组与DDP单药组的3年无进展生存率分别为77.5%和75.0%(P>0.05);PF方案组的中位生存时间为50.6个月,DDP单药组为48.0个月(P>0.05)。两组毒副反应以恶心呕吐、口腔黏膜炎及白细胞减少为主,差异均有统计学意义(P<0.05)。结论 DDP单药与PF方案用于局部晚期鼻咽癌同步放化疗的疗效相近,患者均可耐受,但DDP单药组反应较轻。 Objective To compare the efficacy and safety of single-agent cisplatin(DDP) or DDP plus fluorouracil(5-FU) regimen(PF regimen) combined with concurrent radiotherapy for locally advanced nasopharyngeal carcinoma.Methods Seventy-six patients with locally advanced nasopharyngeal carcinoma were divided into two groups.Forty patients received chemotherapy of PF regimen jointing concurrent radiotherapy(5-FU 500mg/m2 iv d1-d5,cisplatin 80mg/m2 iv d1;21 days was a cycle),and 36 patients received chemotherapy of single cisplatin(DDP 40mg/m2 iv once a week for a total of 7 times) with concurrent radiotherapy;nasopharyngeal lesions and positive lymph node were given a total amount of 70Gy,and prophylactic neck radiation was given the amount of 50Gy.Results The efficacy and toxicities could be evaluated.The response rate(RR) was 100% in the two groups(P0.05).The 1-,3-year overall survival(OS) rate in PF regimen group were 100% and 85%,and in single-agent DDP group were 100% and 89%,respectively(P0.05).3-year disease-free survival rate in PF regimen group and single-agent DDP group were 77.5% and 75.0%,respectively(P0.05).The median OS of PF regimen group and single-agent DDP group were 50.6 months and 48.0 months(P0.05).The main toxicities were nausea/vomiting,oral mucositis and leucopenia.The incidence of them on PF regimen group was higher than that in single-agent DDP group(P0.05).Conclusion For patients with locally advanced nasopharyngeal carcinoma who accepted RT combining concurrent chemotherapy either DDP alone or PF regimen,the efficacy is similar and toxicities can be tolerated.The toxicities in the group of DDP alone are relatively mild.
出处 《临床肿瘤学杂志》 CAS 2012年第3期229-232,共4页 Chinese Clinical Oncology
关键词 局部晚期鼻咽癌 同步放化疗 预后 毒副反应 Locally advanced nasopharyngeal carcinoma Concurrent chemoradiotherapy Prognosis Toxicity
  • 相关文献

参考文献9

  • 1Afqir S,Ismaili N,Errihani H. Concurrent chemoradiotherapy in the nanagement of advanced nasopharyngeal carcinoma:Current status[J].J Can Res Ther,2009,(01):3-7.
  • 2Therasse P,Asrbuck SG,Eisenhauer EA. New guidelines to evaluate t he response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of t he United States,National Cancer Institute of Canada[J].Journal of the National Cancer Institute,2000,(03):205-216.doi:10.1093/jnci/92.3.205.
  • 3National Cancer Institute. Common terminology criteria for adverse events[EB/OL].http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE _4.02 _ 2009-09-15_QuickReference_5x7.pdf,2011.
  • 4Cox JD,Stetz J,Pajak TF. Toxicity criteria of t he Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J].International Journal of Radiation Oncology,Biology,Physics,1995,(05):1341-1346.doi:10.1016/0360-3016(95)00060-C.
  • 5O'Sullivan B. Nasopharynx cancer:Therapeutic value of chemoradiotherapy[J].International Journal of Radiation Oncology,Biology,Physics,2007,(2 Suppl):118-121.
  • 6Thephamongkhol K,Zhou J,Browman G. Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma:A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases[J].Journal of Clinical Oncology,2004,(14 Suppl):a2004.
  • 7Al-Sarraf M,LeBlanc M,Giri PG. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized Intergroup study 0099[J].Journal of Clinical Oncology,1998,(04):1310-1317.
  • 8Langendijk JA,Leemans CR,Buter J. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma:A meta-analysis of the published literature[J].Journal of Clinical Oncology,2004,(22):4604-4612.doi:10.1200/JCO.2004.10.074.
  • 9Mei Q,Hu GY,Long GX. A prospective study on therapeutic gain by concurrent chemoradiotherapy for stage Ⅱ-Ⅳa nasopharyngeal carcinoma[J].Journal of Huazhong University of Science and Technology(Medical Science),2011,(01):58-61.doi:10.1007/sl1596-011-0150-8.

同被引文献89

  • 1李志强,夏云飞.提高鼻咽癌局部控制率的治疗进展[J].广东医学,2005,26(12):1622-1624. 被引量:8
  • 2梁超前.鼻咽癌根治性放疗后复发和(或)转移的再治疗[J].中华肿瘤防治杂志,2006,13(19). 被引量:8
  • 3谢方云,亓姝楠,胡伟汉,邹国荣,彭苗,李济时.泰素帝联合顺铂(TP)与顺铂联合5-FU(PF)方案治疗局部晚期鼻咽癌的比较[J].癌症,2007,26(8):880-884. 被引量:13
  • 4Afqir S,Ismaili N,Errihani H.Concurrent chemoradiotherapy in themanagement of advanced nasopharyngeal carcinoma:current status[J].Journal of cancer research and therapeutics,2009,5(1):3.
  • 5O’Sullivan B.Nasopharynx cancer:therapeutic value ofchemoradiotherapy[J].International Journal of Radiation OncologyBiology Physics,2007,69(2):S118-S121.
  • 6Al-Sarraf M,LeBlanc M,Giri P G,et al.Chemoradiotherapy versusradiotherapy in patients with advanced nasopharyngealcancer:phaseⅢrandomized Intergroup study 0099[J].J Clin Oncol,1998,16(4):1310-1317.
  • 7Wee J,Tan E H,Tai B C,et al.Randomized trial of radiotherapyversus concurrent chemoradiotherapy followed by adjuvantchemotherapy in patients with American Joint Committee on Cancer/In ternational Union against cancer stageⅢandⅣnasopharyngealcancer of the endemic variety[J].J Clin Oncol,2005,23(27):6730-6738.
  • 8Kwong D L,Sham J S,Au G K,et al.Concurrent and adjuvantchemotherapy for nasopharyngeal carcinoma:a factorial study[J].JClin Oncol,2004,22(13):2643-2653.
  • 9Hennequin C.Association of taxanes and radiotherapy:preclinical andclinical studies[J].Cancer Radiother,2004,8(1):95-105.
  • 10EDGE S B,COMPTON C C.The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17:1471-1474.

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部